PDCD1 and head and neck squamous cell carcinoma: The low frequencies of defective MMR in our cohorts were comparable with the reported rate of 1% to 3% in de novo head and neck squamous cell carcinoma.36 Interestingly, our data suggested higher protein expression of PD-1 and gene expression of CD4 in postradiation OCSCC than sporadic tumors.